Home
HelpTest Code PRKAF Fibrolamellar Carcinoma, 19p13.1 (PRKACA) Rearrangement, FISH, Tissue
Reporting Name
PRKACA, Rearrangement, FISH, TsPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Useful For
Aid in the diagnosis of identifying PRKACA gene rearrangements of patients with fibrolamellar carcinoma
Method Name
Fluorescence In Situ Hybridization (FISH)
Necessary Information
1. A pathology report is required in order for testing to be performed. Acceptable pathology reports include working drafts, preliminary pathology or surgical pathology reports.
2. A reason for testing must be provided. If this information is not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Tissue
Container/Tube: Formalin-fixed, paraffin-embedded tumor tissue block
Specimen Type: Slides
Slides/Slide Count: Three consecutive, unstained, 5 micron-thick sections placed on positively charged slides, and 1 hematoxylin and eosin-stained slide
Specimen Type
TissueSpecimen Minimum Volume
Two consecutive, unstained, 5 micron-thick sections placed on positively charged slides, and 1 hematoxylin and eosin-stained slide.
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Tissue | Ambient (preferred) | ||
| Refrigerated | |||
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
An interpretive report will be provided.
Interpretation
A positive result with the PRKACA probe is detected when the percent of cells with an abnormality exceeds the normal cutoff for the probe set.
A positive result of PRKACA suggests fusion of the PRKACA and DNAJB1 genes at 19p13.1. A negative result suggests no fusion of the PRKACA and DNAJB1 genes has occurred.
Day(s) Performed
Monday through Friday
Report Available
7 to 10 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88271x2, 88291-DNA probe, each (first probe set), Interpretation and report
88271x2-DNA probe, each; each additional probe set (if appropriate)
88271x1-DNA probe, each; coverage for sets containing 3 probes (if appropriate)
88271x2-DNA probe, each; coverage for sets containing 4 probes (if appropriate)
88271x3-DNA probe, each; coverage for sets containing 5 probes (if appropriate)
88274-w/modifier 52 -Interphase in situ hybridization, <25 cells, each probe set (if appropriate)
88274-Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)
88275-Interphase in situ hybridization, 100 to 300 cells, each probe set (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| PRKAF | PRKACA, Rearrangement, FISH, Ts | 104670-5 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 40669 | Result Summary | 50397-9 |
| 40670 | Interpretation | 69965-2 |
| 40671 | Result | 62356-1 |
| 40672 | Reason for Referral | 42349-1 |
| 40673 | Specimen | 31208-2 |
| 40674 | Source | 31208-2 |
| 40675 | Tissue ID | 80398-1 |
| 40676 | Method | 85069-3 |
| 40677 | Additional Information | 48767-8 |
| 40678 | Disclaimer | 62364-5 |
| 40679 | Released By | 18771-6 |
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| _PBCT | Probe, +2 | No | No |
| _PADD | Probe, +1 | No | No |
| _PB02 | Probe, +2 | No | No |
| _PB03 | Probe, +3 | No | No |
| _IL25 | Interphases, <25 | No | No |
| _I099 | Interphases, 25-99 | No | No |
| _I300 | Interphases, >=100 | No | No |
Testing Algorithm
This test does not include a pathology consultation. If a pathology consultation is requested, PATHC / Pathology Consultation should be ordered, and the appropriate fluorescence in situ hybridization test will be performed at an additional charge.
Appropriate ancillary probes may be performed at consultant discretion to render comprehensive assessment. Any additional probes will have the results included within the final report and will be performed at an additional charge.